Hemispherx Biopharma, Inc. (NYSE:HEB) tinted gains of +3.21% (+0.01 points) to US$0.23. The volume of 0.09 Million shares climbed down over an trading activity of 313.06 Million shares. EPS ratio determined by looking at last 12 month figures is -0.26. Over the same time span, the stock marked US$0.59 as its best level and the lowest price reached was US$0.15. The corporation has a market cap of US$10.84 Million.
Hemispherx Biopharma, Inc. (NYSE:HEB)’s earnings per share has been growing at a 27.9 percent rate over the past 5 year when average revenue increase was noted as 15.5 percent. The return on equity ratio or ROE stands at -118.5 percent while most common profitability ratio return on investment (ROI) was -108.7 percent. The company’s institutional ownership is monitored at 7.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Ultrapar Participacoes S.A. (NYSE:UGP) is worth US$8.74 Billion and has recently risen 3.2% to US$15.78. The latest exchange of 0.65 Million shares is below its average trading activity of 918.23 Million shares. The day began at US$15.63 but the price moved to US$15.56 at one point during the trading and finally capitulating to a session high of US$15.8. The stock tapped a 52-week high of US$25.9 while the mean 12-month price target for the shares is US$15.6.
Currently, the stock carries a price to earnings ratio of 31, a price to book ratio of 3.51, and a price to sales ratio of 0.37. For the past 5 years, the company’s revenue has grown 8.2%, while the company’s earnings per share has grown 8.7%. With an institutional ownership near 5.2%, it carries an earnings per share ratio of 0.51.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.